SEC Form 4 · accession 0001209191-15-061166
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Howard W Robin
Officer — President & CEO · Director
Period of report
Jul 14, 2015
Accepted (ET)
Jul 16, 2015 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 14, 2015 | M | 58,334 | $6.98 | A | 68,334 | D | |
| Common StockF1,F2 | Jul 14, 2015 | S | 58,334 | $11.78 | D | 10,000 | D | |
| Common Stock | holding | — | — | — | 410 | I | by spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $6.98 | Jul 14, 2015 | M | 58,334 | D | Dec 21, 2011 | Dec 20, 2015 | Common Stock | 58,334 | 641,666 | D |
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan for stock options scheduled to expire in 2015 as described in the Current Report on Form 8-K filed by Nektar Therapeutics on July 16, 2015.
- F2This transaction was executed in multiple trades at prices ranging from $11.56 to $11.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.